ndothelial dysfunction, as defined by a decreased bioavailability of NO, is one of the earliest steps in the development of atherosclerosis. 1, 2 The resulting vascular inflammation including accumulation of lipid-laden macrophages hallmarks the pathology underlying the major clinical complications of cardiovascular disease. Many of the key players in these inflammatory events have been identified and validated in vivo, with a clear focus on the endothelial adhesion molecules like VCAM-1, the macrophage lipid handling machinery and inflammatory mediators like various chemokines that attract a variety of leukocytes to the atherosclerotic lesion. 3 In the current issue of Circulation Research, Romeo et al 4 identify a quite unexpected protein to play a pivotal role in these processes. Mice with a partial deletion of profilin-1 (Pfn1), an actin binding molecule that is involved in the dynamics of the actin cytoskeleton ( Figure) , are shown to be substantially protected against atherosclerosis. This is the second example for a prominent role of an actin binding molecule in cardiovascular disease, given the recent excitement regarding the potential implication for regenerative medicine of thymosin beta-4 ( Figure 1 ), because of its action in preventing ischemic damage to myocardium and inducing cardiac neovascularization. 5, 6 Romeo et al 4 show that, when placed on an atherogenic diet for 2 months, Pfn -/ϩ Ldlr Ϫ/Ϫ mice exhibit remarkably decreased initial lesion sizes at atherosclerosis-prone sites in both the descending aorta, and the aortic arch and brachiocephalic artery. Consistent with current understanding, these early lesions indeed coincide with sites of disturbed flow profiles. 2 They next go on to convincingly display several mechanistic insights into the causes of this protective effect of diminished profilin-1 levels. Endothelial NO production is preserved in the Pfn -/ϩ Ldlr Ϫ/Ϫ mice under dietary conditions that would normally severely comprise its production, and the accumulation of monocytes is partially prevented by a decreased expression of VCAM-1. In addition, the macrophages are less able to load lipids because of a partial inhibition of CD36-driven endocytosis of oxidized LDL. As before, profilin-1 is shown to be induced at these vascular sites in both the Pfn ϩ/ϩ and Pfn ϩ/Ϫ mice, albeit to a much decreased level in the latter. 4, 7 What is causing this inhibitory effect on the earliest stages of atherogenesis? At a molecular signaling level, blunted inflammatory responses are ascribed to an attenuated activation of the p38 MAPK-ATF-2 axis, whereas effects on nuclear factor kappa B or c-Jun N-terminal kinase activity seem absent. The latter finding is consistent with recent findings on the specific localization of active phospho-ATF-2 in endothelium overlying early atherosclerotic lesions (and its absence in nonaffected endothelium) and the documented link of p38 MAPK-driven inflammatory gene expression to proatherogenic flow profiles. 8, 9 The concomitant prominent role of ATF-2 in the expression of proinflammatory gene expression in endothelium was shown to be related to the absence of the shear-induced transcription factor KLF2, a factor that, like shear itself, has an enormous impact on the architecture of the actin cytoskeleton. 8, 10 Collectively, the findings by Romeo et al 4 clearly set the stage for a prominent role of the actin cytoskeleton in modulating many unexpected aspects of the atherosclerosis process. Still, although a number of molecular mediators are identified, the intriguing question remains how these effects are produced by an actin-binding molecule. The authors suggest that these effects might be linked to a more promiscuous binding behavior of profilin-1 to nonactin molecules through its well known proline-rich peptide binding domain. 11 Unfortunately, most of the circumstantial evidence for such elusive binding partners is extrapolated from the properties of its brain-specific homologue profilin-2, whereas profilin-1 seems much more restricted in its affinity for actin in vivo. 12 Can subtle changes in actin cytoskeleton dynamics through an altered level of profilin-1 explain the observed effects in vivo? Despite 3 decades of work unraveling the biochemistry of actin fiber dynamics and the role of profilin therein, a link to cellular signaling, let alone in vivo roles in (patho-)physiology and disease remain obscure. 13, 14, 15 Unfortunately, the effect of partial profilin-1 deficiency on the architecture and dynamics of the in vivo actin cytoskeleton has not been documented in the present study by Romeo et al. 4 Still, a plethora of potential links to atherosclerosis seem at hand. Disturbed hemodynamics at atherosclerosis prone areas of the vasculature have been linked to both endothelial dysfunction and effects on the cytoskeleton. 2, 16 Indeed, the actin network itself has been proposed to be the most plausible mechanosensor, directly linking mechanical forces to signal transduction via integrin stimulation. 17, 18, 19 Stress fibers are modulated by altered shear forces and they themselves have been shown to alter the localization of important inflammatory members of the MAPK signaling network,
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including p38-MAPK and c-Jun N-terminal kinase. 20 The shear-induced, atheroprotective transcription factor KLF2 has severe effects on the actin cytoskeletal architecture and on nuclear exclusion of p-AFT2. 8, 10 In addition, even the effects on macrophage lipid metabolism could be explained by altered actin dynamics, as endocytosis and short-range vesicular transport are known to be mediated by actin-dependent myosin-V, preceding transfer to microtubules for long range transport. 21 Thus, interfering with endocytosis events would explain the reported reduced levels of CD36 at the plasma membrane and compromised lipid import. 4 In this respect, it is noteworthy that both crucial mediators identified by Romeo et al, 4 eNOS and CD36, are (partial) residents of caveolae. Profilin-1 deficiency is now shown to sustain eNOS phosphorylation and activity under atherogenic dietary conditions, which greatly influence the high cholesterol lipid composition of caveolae as well as eNOS localization. 23 As transport of caveolae and eNOS to and from the Golgi are dependent on actin and myosin-VI, interfering with actin dynamics would alter the eNOS distribution between these cellular compartments thereby affecting its activity. 22, 23 In conclusion, the article by Romeo et al 4 has now provided the first in vivo evidence for a prominent effector role of profilin-1 in cardiovascular disease and has linked the actin cytoskeleton and its dynamics directly to vascular inflammation. This sets the stage for examining in much more detail the close molecular links between the actin cytoskeleton and vascular inflammation as such detailed knowledge will be crucial for finding a practical medical application of these findings. This in view of the essential role of profilin-1 in both embryogenesis and all cell division processes in adult life, as evidenced by the embryonic lethality of the full Pfn Ϫ/Ϫ knockout attributable to defective cytokinesis. 24 One pivotal issue being the regulation of the Pfn1 gene, and how this connects to the observed increase in vascular expression in response to an atherogenic diet. 4, 7 This will provide potential innovative handles to more subtly and specifically influence these processes in a way that would be beneficial for patients suffering from atherosclerosis and its complications.
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The pivotal role of profilin-1 in actin dynamics and its cardiovascular effects. Profilin-1 greatly increases the rate of actin polymerization by both binding actin-ADP to catalyze nucleotide exchange to yield actin-ATP and by acting as the substrate of the processive actinpolymerising enzyme Formin, which adds actin-ATP to the barbed ends of (newly) formed actin fibers, with a concerted release of profilin. In addition, in the absence of growing actin fibers, profilin sequesters actin-ATP in the cytoplasm to prevent spontaneous, uncatalysed polymerization allowing the cell to maintain a high concentration of actin-ATP, ready to be incorporated when a new actin fiber is nucleated. In mammalian cells, a large portion of actin-ATP is transferred from profilin to thymosin-beta4, where it is prevented from both spontaneous and from formin-catalyzed incorporation into actin-fibers, because the actin-thymosin dimer cannot act as a substrate for formin. [13] [14] [15] Organization for Scientific Research (Genomics grant 050-10-014), The SenterNovem IOP-Genomics Program (IGE03012C), and the EU European Vascular Genomics Network (LSHM-CT-2003-503254).
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